Long-term Outcome and Prediction Models of Activities of Daily Living in Alzheimer Disease With Cholinesterase Inhibitor Treatment.

Research output: Contribution to journalArticlepeer-review

39 Citations (SciVal)

Abstract

In untreated patients with Alzheimer disease (AD) the functional ability is gradually lost. What happens to the patients after continuous long-term cholinesterase inhibitor (ChEI) treatment is less investigated. The objective of this study was to describe the longitudinal functional outcome and analyze factors affecting the outcome in ChEI-treated patients. In an open, 3-year, nonrandomized, prospective, multicenter study in a routine clinical setting, 790 patients were treated with either donepezil, rivastigmine, or galantamine. At baseline and every 6 months, they were assessed with several rating scales including Instrumental Activities of Daily Living (IADL), Physical Self-Maintenance Scale (PSMS), and Mini-Mental State Examination (MMSE). A faster functional decline was associated with lower cognitive ability at baseline, older age, and the interaction of higher education and longer time in the study. The patients residing with a spouse or relative showed slower deterioration in IADL score. A higher mean dose of ChEI, regardless of drug agent, was also related to slower instrumental ADL decline. Prediction models for longitudinal functional outcome were provided. AD severity at baseline is a key factor in obtaining reliable clinical prognoses of the long-term ADL ability. The dosage of ChEI treatment could possibly lead to a different functional outcome.
Original languageEnglish
Pages (from-to)63-72
JournalAlzheimer Disease and Associated Disorders
Volume25
Issue number1
DOIs
Publication statusPublished - 2011

Subject classification (UKÄ)

  • Clinical Medicine
  • Neurology

Keywords

  • Alzheimer's disease
  • activities of daily living
  • cholinesterase inhibitors
  • longitudinal study
  • statistical models
  • disease progression.

Fingerprint

Dive into the research topics of 'Long-term Outcome and Prediction Models of Activities of Daily Living in Alzheimer Disease With Cholinesterase Inhibitor Treatment.'. Together they form a unique fingerprint.

Cite this